Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Correction of Stockwatch’s Hugely Erroneous Press Release Title
-
Globex Engages Canaccord Genuity as Financial Advisor
-
Vanstar Announces the Appointment of Mr. Sébastien Plouffe as Director and VP Public Relations
-
Sprout Social Announces Launch of Initial Public Offering
-
Form 8.3 - Accesso Technology Group plc
-
WeedMD Announces Strategic Combination with Starseed Holdings Inc. and Secures $25 Million Cornerstone Investment
-
Transaction in Own Shares
-
Quebec Precious Metals Announces Closing of $6.5 Million Bought Deal Private Placement; Newmont Goldcorp Increases Ownership to 19.9%
-
Form 8.3 - Accesso Technology Group plc
-
Wave of European Cannabis firms to list in 2020, analyst says
-
3iQ Files The Bitcoin Fund IPO
-
Form 8.3 - Accesso Technology Group plc
-
PayPoint plc:Results for the six months to 30 September 2019
-
Evolent Health (EVH) PT Lowered to $16 at Canaccord Genuity
-
Form 8.3 - Accesso Technology Group plc
-
Golden Dawn Receives Exploration Permit for Lexington Area
-
Middlefield Global Real Asset Fund IPO Raises $110 Million
-
X4 Pharmaceuticals (XFOR) Prices Offering at $12/Share w/Warrants
-
X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants
-
Net Asset Value(s)
-
Director Declaration: Additional Directorship
-
ChemoCentryx (CCXI) PT Raised to $48 at Canaccord Genuity
-
Form 8.3 - Accesso Technology Group plc
-
X4 Pharmaceuticals (XFOR) to Offer Common Stock and Warrants
-
X4 Pharmaceuticals Announces Proposed Public Offering
-
Canaccord Genuity Reiterates Buy Rating on Detour Gold Corp. (DGC:CN) (DRGDF)
-
Canaccord Genuity Reiterates Buy Rating on Alimentation Couche-Tard Inc (ATD/B:CN) (ANCUF)
-
Royal Gold (RGLD) PT Lowered to $125 at Canaccord Genuity
-
Osisko Gold Royalties Ltd. (OR:CN) (OR) PT Lowered to Cdn$18 at Canaccord Genuity
-
Altius Minerals Corp (ALS:CN) (ATUSF) PT Lowered to Cdn$17.50 at Canaccord Genuity
-
Transaction in Own Shares
-
Harpoon Therapeutics (HARP) PT Raised to $26 at Canaccord Genuity
-
Canaccord Genuity Reiterates Hold Rating on Titan Mining Corp. (TI:CN) (TNMCF)
-
AMEX Announces Partial Exercise of Underwriter’s Option for Additional Gross Proceeds of $981,900 and Aggregate Gross Proceeds of $8,982,000
-
Discovery 2019 Short Duration LP Closes IPO
-
Canaccord Genuity Reiterates Buy Rating on Cree (CREE) Following Analyst Day
-
Form 8.3 - Accesso Technology Group plc
-
Atalaya Mining PLC Announces Third Quarter Financial Results
-
Canaccord Genuity Reiterates Buy Rating on Docebo Inc. (DCBO:CN)
-
Net Asset Value(s)
-
Canaccord Genuity Reiterates Spec. Buy Rating on PetroShale (PSH:CN) (PSHIF)
-
BTIG Announces Expansion of Equity Research Division with Consumer Lifestyle and Wellness Brands Analyst Camilo Lyon
-
Form 8.3 - Accesso Technology Group plc
-
CRISPR Therapeutics (CRSP) PT Raised to $80 at Canaccord Genuity
-
MAXIMUS, Inc. (MMS) PT Lowered to $76 at Canaccord Genuity
-
Regulus Resources (REG:CN) (RGLSF) PT Raised to Cdn$2.75 at Canaccord Genuity
-
Canaccord Genuity Reiterates Buy Rating on Corus Entertainment (CJR/B:CN) (CJREF)
-
binx health To Present At The Canaccord Genuity Medical Technology And Diagnostics Forum
-
Orchestra BioMed™ to Present at the Canaccord Genuity MedTech and Diagnostics Forum and the 31st Annual Piper Jaffray Healthcare Conference
-
Form 8.3 - Accesso Technology Group plc

